Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Understanding the pharmacogenetic approach to warfarin dosing.

Glurich I, Burmester JK, Caldwell MD.

Heart Fail Rev. 2010 May;15(3):239-48. doi: 10.1007/s10741-008-9115-9. Epub 2008 Nov 8. Review.

PMID:
18998206
2.

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

Carlquist JF, Horne BD, Muhlestein JB, Lappé DL, Whiting BM, Kolek MJ, Clarke JL, James BC, Anderson JL.

J Thromb Thrombolysis. 2006 Dec;22(3):191-7.

PMID:
17111199
3.

Pathology consultation on warfarin pharmacogenetic testing.

Stack G; Education Committee of the Academy of Clinical Laboratory Physicians and Scientists.

Am J Clin Pathol. 2011 Jan;135(1):13-9. doi: 10.1309/AJCPAO82OTNPUBLW. No abstract available.

PMID:
21173120
4.

Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.

Daly AK.

Arch Toxicol. 2013 Mar;87(3):407-20. doi: 10.1007/s00204-013-1013-9. Epub 2013 Feb 2. Review.

PMID:
23376975
5.

An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.

Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL.

Thromb Haemost. 2008 Aug;100(2):229-39.

PMID:
18690342
6.

[Application of warfarin pharmacogenetics].

Tomek A, Mat'oska V, Kumstýrfová T, Táborský L.

Vnitr Lek. 2009 Jun;55(6):565-9. Review. Czech.

PMID:
19662888
7.

Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Stehle S, Kirchheiner J, Lazar A, Fuhr U.

Clin Pharmacokinet. 2008;47(9):565-94. Review.

PMID:
18698879
8.

Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation.

Xu Q, Xu B, Zhang Y, Yang J, Gao L, Zhang Y, Wang H, Lu C, Zhao Y, Yin T.

Thromb Haemost. 2012 Dec;108(6):1132-40. doi: 10.1160/TH12-05-0362. Epub 2012 Sep 26.

PMID:
23015069
9.

Warfarin pharmacogenetics: does more accurate dosing benefit patients?

Eby C.

Semin Thromb Hemost. 2012 Oct;38(7):661-6. doi: 10.1055/s-0032-1326789. Epub 2012 Oct 9. Review.

10.

Role of warfarin pharmacogenetic testing in clinical practice.

Tan GM, Wu E, Lam YY, Yan BP.

Pharmacogenomics. 2010 Mar;11(3):439-48. doi: 10.2217/pgs.10.8. Review.

PMID:
20402581
11.

The long and winding road to warfarin pharmacogenetic testing.

Ginsburg GS, Voora D.

J Am Coll Cardiol. 2010 Jun 22;55(25):2813-5. doi: 10.1016/j.jacc.2010.04.006. No abstract available.

12.

Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.

Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M, Valdes R Jr.

Pharmacogenomics. 2008 Feb;9(2):169-78. doi: 10.2217/14622416.9.2.169.

PMID:
18370846
13.

A randomized controlled trial of genotype-based Coumadin initiation.

Burmester JK, Berg RL, Yale SH, Rottscheit CM, Glurich IE, Schmelzer JR, Caldwell MD.

Genet Med. 2011 Jun;13(6):509-18. doi: 10.1097/GIM.0b013e31820ad77d.

PMID:
21423021
14.

Warfarin pharmacogenetics.

Limdi NA, Veenstra DL.

Pharmacotherapy. 2008 Sep;28(9):1084-97. doi: 10.1592/phco.28.9.1084. Review.

15.

Pharmacogenetic-based dosing of warfarin.

[No authors listed]

Med Lett Drugs Ther. 2008 May 19;50(1286):39-40. No abstract available.

PMID:
18487958
16.

VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study.

Zambon CF, Pengo V, Padrini R, Basso D, Schiavon S, Fogar P, Nisi A, Frigo AC, Moz S, Pelloso M, Plebani M.

Pharmacogenomics. 2011 Jan;12(1):15-25. doi: 10.2217/pgs.10.162.

PMID:
21174619
17.

Genetic influences on the response to warfarin.

Kamali F.

Curr Opin Hematol. 2006 Sep;13(5):357-61. Review.

PMID:
16888441
18.

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R, Lee SC.

Clin Pharmacol Ther. 2006 Oct;80(4):346-55.

PMID:
17015052
19.

A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism.

Wells PS, Majeed H, Kassem S, Langlois N, Gin B, Clermont J, Taljaard M.

Thromb Res. 2010 Jun;125(6):e259-64. doi: 10.1016/j.thromres.2009.11.020. Epub 2010 Apr 24.

PMID:
20421126
20.

Pharmacogenomic testing for warfarin dosing: we are ready now.

Wu AH.

Expert Rev Cardiovasc Ther. 2009 Dec;7(12):1483-5. doi: 10.1586/erc.09.117. No abstract available.

PMID:
19954308

Supplemental Content

Support Center